BioMarin Pharmaceutical(BMRN) - 2022 Q4 - Annual Report

We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations. • trade protection measures and import or export licensing requirements; • changes in international medical reimbursement policies and programs; Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. For example, Russia's invasion of Ukraine a ...